Version 1
: Received: 23 September 2024 / Approved: 23 September 2024 / Online: 24 September 2024 (04:46:40 CEST)
How to cite:
Randall-Demllo, S.; Al-Qadami, G.; Raposo, A. E.; Ma, C.; Priebe, I.; Hor, M.; Singh, R.; Fung, K. Y. Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing. Preprints2024, 2024091839. https://doi.org/10.20944/preprints202409.1839.v1
Randall-Demllo, S.; Al-Qadami, G.; Raposo, A. E.; Ma, C.; Priebe, I.; Hor, M.; Singh, R.; Fung, K. Y. Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing. Preprints 2024, 2024091839. https://doi.org/10.20944/preprints202409.1839.v1
Randall-Demllo, S.; Al-Qadami, G.; Raposo, A. E.; Ma, C.; Priebe, I.; Hor, M.; Singh, R.; Fung, K. Y. Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing. Preprints2024, 2024091839. https://doi.org/10.20944/preprints202409.1839.v1
APA Style
Randall-Demllo, S., Al-Qadami, G., Raposo, A. E., Ma, C., Priebe, I., Hor, M., Singh, R., & Fung, K. Y. (2024). Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing. Preprints. https://doi.org/10.20944/preprints202409.1839.v1
Chicago/Turabian Style
Randall-Demllo, S., Rajvinder Singh and Kim Y.C. Fung. 2024 "Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing" Preprints. https://doi.org/10.20944/preprints202409.1839.v1
Abstract
Despite improvements in participation in population-based screening programs, colorectal cancer remains a major cause of cancer-related mortality worldwide. Targeted interventions are desirable to reduce the health and economic burden of this disease. Two-dimensional monolayers of colorectal cancer cell lines represent the traditional in vitro models for disease and are often used for diverse purposes, including delineation of molecular pathways associated with disease aetiology or to gauge drug efficacy. The lack of complexity in such models, chiefly the limited epithelial cell diversity and differentiation, attenuated mucus production, lack of microbial interactions and mechanical stresses, has driven interest in development of more holistic and physiologically relevant in vitro model systems. In particular, established ex vivo patient-derived explant and patient-derived tumour xenograft models have been supplemented by progress in organoid and microfluidic organ-on-a-chip cultures. Here we discuss the applicability of advanced culturing technologies, such as organoid systems, as models for colorectal cancer and for testing chemotherapeutic drug sensitivity and efficacy. We highlight current challenges associated with organoid technologies and discuss their future for more accurate disease modelling and personalized medicine.
Keywords
intestinal organoid; 3D culture; colorectal cancer; organ-on-a-chip; disease modelling; therapeutic screening; ex vivo models
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
